Recent advances in CAR T-cell engineering using synthetic biology: Paving the way for next-generation cancer treatment.
CAR T-Cell
Cancer
Synthetic biology
Therapy
Treatment
Journal
Advances in protein chemistry and structural biology
ISSN: 1876-1631
Titre abrégé: Adv Protein Chem Struct Biol
Pays: Netherlands
ID NLM: 101497281
Informations de publication
Date de publication:
2024
2024
Historique:
medline:
19
5
2024
pubmed:
19
5
2024
entrez:
18
5
2024
Statut:
ppublish
Résumé
This book chapter highlights a comprehensive exploration of the transformative innovations in the field of cancer immunotherapy. CAR (Chimeric Antigen Receptor) T-cell therapy represents a groundbreaking approach to treat cancer by reprogramming a patient immune cells to recognize and destroy cancer cells. This chapter underscores the critical role of synthetic biology in enhancing the safety and effectiveness of CAR T-cell therapies. It begins by emphasizing the growing importance of personalized medicine in cancer treatment, emphasizing the shift from one-size-fits-all approaches to patient-specific solutions. Synthetic biology, a multidisciplinary field, has been instrumental in customizing CAR T-cell therapies, allowing for fine-tuned precision and minimizing unwanted side effects. The chapter highlights recent advances in gene editing, synthetic gene circuits, and molecular engineering, showcasing how these technologies are optimizing CAR T-cell function. In summary, this book chapter sheds light on the remarkable progress made in the development of CAR T-cell therapies using synthetic biology, providing hope for cancer patients and hinting at a future where highly personalized and effective cancer treatments are the norm.
Identifiants
pubmed: 38762281
pii: S1876-1623(24)00012-9
doi: 10.1016/bs.apcsb.2024.02.003
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
91-156Informations de copyright
Copyright © 2024. Published by Elsevier Inc.